Clinical trials: Plaque Psoriasis
Psoriasis
Etanercept (Enbrel®) in Psoriasis - Pediatrics
This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.
- Trial name
- NCT00078819
- Testing
- Etanercept
- Volunteers
- 211 people
- Sponsor
- Amgen
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Plaque Psoriasis
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts.
- Trial name
- NCT06808815
- Testing
- DC-806
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Psoriasis
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of plaque psoriasis when applied twice daily for 6 weeks.
- Trial name
- NCT01993433
- Testing
- DRM02, Vehicle
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Dermira, Inc.
Psoriasis, Parapsoriasis
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab.
- Trial name
- NCT00106847
- Testing
- Infliximab
- Volunteers
- 683 people
- Sponsor
- Centocor, Inc.
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Psoriasis
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and…
- Trial name
- UNMASK2 (NCT04894890)
- Testing
- secukinumab
- Where
- 42 sites in China
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
- Trial name
- NCT02134210
- Testing
- Etanercept, CHS-0214
- Where
- 100 sites in United States, Australia and 5 more
- Volunteers
- 521 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some…
- Trial name
- NCT01704599
- Testing
- Humira Then Humira plus 3 B vitamins
- Volunteers
- 8 people
- Sponsor
- Wayne State University
Moderate-to-Severe Plaque Psoriasis
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and…
- Trial name
- PSO (NCT04612699)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Moderate to Severe Plaque Psoriasis
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06943950
- Testing
- SYHX1901
- Volunteers
- 500 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04967508
- Testing
- Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar)
- Where
- 32 sites in Czechia, Estonia and 6 more
- Volunteers
- 503 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis Vulgaris
Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris
The purpose of this study is to investigate whether light therapy can help improve plaque psoriasis. This is a study based on a new medical device. The device produces its light from light emitting diodes.
- Trial name
- NCT03507946
- Testing
- Dermawrap - combined 460nm, 633nm and 830nm LED therapy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ismart
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Psoriasis
The Effect of Alga Dunaliella Bardawil on Psoriasis
This is a double blind, parallel group, randomized study with 12 weeks of daily oral administration of Dunaliella or placebo in psoriasis patients.
- Trial name
- NCT01628081
- Testing
- Dunaliella Bardawil
- Where
- 2 sites in Israel
- Volunteers
- 46 people
- Sponsor
- Sheba Medical Center
Psoriatic Arthritis (PsA)
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have…
- Trial name
- NCT07869134
- Testing
- FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2
- Volunteers
- 210 people
- Sponsor
- Forward Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.